Newswire (Published: Friday, October 13, 2017, Received: Friday, October 6, 2017, 1:41:25 AM CDT)

Word Count: 375

By a News Reporter-Staff News Editor at Drug Week -- Investigators discuss new findings in Oncology - Prostate Cancer. According to news reporting originating in Zabrze, Poland, by NewsRx journalists, research stated, "Numerous data suggest that an increase of cancer stem cells (CSCs) in tumor mass can be the reason for failure of conventional therapies because of their resistance. CD44+/CD24- cells are a putative cancer stem cells subpopulation in prostate cancer."

The news reporters obtained a quote from the research from the Medical University of Silesia, "TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) is an activator of apoptosis in tumor cells. However, some tumors are TRAIL-resistant. Cancer cells can be re-sensitized to TRAIL induced apoptosis by a combination of TRAIL and taxanes. The aim of this work was to analyze the enhancement of the anticancer effect of TRAIL by paclitaxel, cabazitaxel and docetaxel in the whole population of PC3 and DU145 prostate cancer cells, but also in CD44+/CD24- prostate cancer stem cells. We examined the apoptotic effect of TRAIL and taxanes using flow cytometry and Annexin-V-PE staining. The co-treatment with taxanes and TRAIL enhanced significantly the apoptosis in CD44+/CD24- cells only in PC3 cell line but not in DU145 cells. We discovered also that taxanes can increase the expression of death receptor TRAIL-R2 in PC3 prostate cancer cells."

According to the news reporters, the research concluded: "The results of our study show that treatment with paclitaxel, cabazitaxel and docetaxel is able to enhance the apoptosis induced by TRAIL even in prostate cancer stem cells."

For more information on this research see: Targeting Apoptotic Activity Against Prostate Cancer Stem Cells. International Journal of Molecular Sciences, 2017;18(8):844-864. International Journal of Molecular Sciences can be contacted at: Mdpi Ag, St Alban-Anlage 66, Ch-4052 Basel, Switzerland (see also Oncology - Prostate Cancer).

Our news correspondents report that additional information may be obtained by contacting D. Jaworska, Medical University of Silesia, Sch Med, Div Dental Zabrze, Dept. of Microbiol & Immunol, PL-41808 Zabrze, Poland.

Keywords for this news article include: Zabrze, Poland, Europe, Prostatic Neoplasms, Stem Cell Research, Prostate Cancer, Apoptosis, Oncology, Medical University of Silesia.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

Places

Eastern Europe
Western Europe
Switzerland
Poland
Europe
Basel

Subjects

Science and Technology
      Scientific Research
Health and Wellness
      Medical Conditions and Diseases
            Cancer
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
      Health Sciences
            Medical Research
      Treatments and Therapies
            Growth Factors and Cytokines